glp 1 drugs pancreatitis Adverse effects of GLP-1 class drugs. Gastrointestinal issues are Wonderful new analysis: GLP-1RAs are

simultaneously, IBD-related genetic markers (NOD2, IL23R) influence baseline gut barrier function and inflammatory state

Wael Mctabi and Dr

Weight loss from GLP-1 medications does not produce a disproportionate reduction in muscle mass or function in either obese mice or humans

Biomed Res Int 17(2021):3361309 Mabilleau G, Mieczkowska A, Chappard D (2014) Use of glucagon-like peptide-1 receptor agonists and bone fractures: a meta-analysis of randomized clinical trials

BMJ 341:c2701 Manfield JH et al (2017) Bariatric surgery or non-surgical weight loss for idiopathic intracranial hypertension

53 Future Directions and Unanswered Questions Despite recent evidence from clinical trials, key questions remain about the optimal use of GLP-1RAs for HF